- ￥1980
- EK-Bioscience
- CCC-Y1385
- 2025年07月16日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 规格：
T25
NCI-H2452/NCI-H2452细胞系/NCI-H2452细胞株/NCI-H2452人间皮瘤细胞
Cell line name NCI-H2452
Synonyms H2452; H-2452; NCIH2452
Accession CVCL_1553
Resource Identification Initiative To cite this cell line use: NCI-H2452 (RRID:CVCL_1553)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: TCGA-110-CL cell line panel.
Population: Caucasian.
Doubling time: 48 hours (PubMed=25984343).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Lung, pleura; UBERON=UBERON_0000977.
Sequence variations
Gene deletion; HGNC; 950; BAP1; Zygosity=Heterozygous (PubMed=21642991).
Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=21642991).
Mutation; HGNC; 950; BAP1; Simple; p.Ala95Asp (c.284C>A); Zygosity=Heterozygous (PubMed=21642991; PubMed=26011428).
HLA typing Source: PubMed=26589293
Class I
HLA-A A*01:01,02:01
HLA-B B*35:01,57:01
HLA-C C*04:01,06:02
Genome ancestry Source: PubMed=30894373
Origin % genome
African 0.27
Native American 0
East Asian, North 1.66
East Asian, South 0
South Asian 0
European, North 63.32
European, South 34.76
Disease Pleural biphasic mesothelioma (NCIt: C45665)
Pleural mesothelioma (ORDO: Orphanet_50251)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling Adult
Category Cancer cell line
STR profile Source(s): ATCC=CRL-5946; CLS=300391; Cosmic-CLP=908462; PubMed=25877200
Markers:
Amelogenin X,Y
CSF1PO 11,12
D2S1338 20
D3S1358 17
D5S818 11,12
D6S1043 11,12
D7S820 9,11
D8S1179 10
D12S391 17.3,21
D13S317 12
D16S539 11,13
D18S51 15
D19S433 13
D21S11 28,32.2
FGA 23
Penta D 9
Penta E 12,15
TH01 6,9.3
TPOX 8,11
vWA 17,18
Run an STR similarity search on this cell line
Publications
PubMed=7695406; DOI=10.1016/0003-4975(95)00045-M
Pass H.I., Stevens E.J., Oie H.K., Tsokos M.G., Abati A.D., Fetsch P.A., Mew D.J.Y., Pogrebniak H.W., Matthews W.J.
Characteristics of nine newly derived mesothelioma cell lines.
Ann. Thorac. Surg. 59:835-844(1995)
PubMed=8806092; DOI=10.1002/jcb.240630505
Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.
NCI-Navy Medical Oncology Branch cell line data base.
J. Cell. Biochem. Suppl. 24:32-91(1996)
PubMed=11030152; DOI=10.1038/sj.onc.1203815
Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Oncogene 19:4632-4639(2000)
PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=21245096; DOI=10.1158/0008-5472.CAN-10-2164
Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T., Akatsuka S., Horio Y., Hida T., Kondo Y., Toyokuni S., Osada H., Sekido Y.
LATS2 is a tumor suppressor gene of malignant mesothelioma.
Cancer Res. 71:873-883(2011)
PubMed=21642991; DOI=10.1038/ng.855; PMCID=PMC4643098
Bott M.J., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L., Creaney J., Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R., Powell S.N., Zhou Q., Shen R.-L., Olshen A.B., Rusch V.W., Ladanyi M.
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
Nat. Genet. 43:668-67
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验*发表【中文论文】请标注：由上海酶研生物科技有限公司提供；
*发表【英文论文】请标注：From Shanghai EK-Bioscience Biotechnology Co., Ltd.
都是贴壁细胞，在消化传代过程中，步骤如下：倒尽旧的培养液－＞用无血清的培养基清洗一两次－＞加入一定量的胰酶，置于37度培养箱中5--10分钟，使细胞悬浮－＞显微镜下观察，待细胞大部分变圆时，回到超静台－＞加入一定量的含血清的新培养液，以终止胰酶作用－＞反复吹打细胞－＞再置显微镜下观察，直到细胞全部悬浮起来－＞吸出一部分加入新的培养瓶中－＞最后再补充加入一定量新的培养液。注意： 1、吹细胞时尽量多吹边角儿，此处细胞生长的多。2、吸出细胞前要混匀，可以剧烈震荡培养瓶。3、我们用的是DMEM
方法1、培养液中按1%的体积加双抗（含青霉素1万U/ml，链霉素0.01g/ml）及肝素液（含肝素100U/ml）。用3.5%NaHCO3液调pH值为7.2~7.4，然后加灭活的小牛血清，使浓度为20%。再加PHA（50U~75U/ml），无菌分装于培养瓶内，每瓶1ml。2、无菌操作采血，并以肝素抗凝，同时进行白细胞计数及分类计数。3、取0.1ml抗凝血，加入到含1ml培养液的培养瓶中，每个血样接2~3个培养瓶。如果以血浆或分离的淋巴细胞代替全血，加入培养瓶中更好。4、37℃培养72h，在培养结束前16h
一、实验材料NCI-H1299，购自上海晶莱生物技术有限公司。表 2.1.1 主要试剂试剂与耗材厂家（货号）细胞培养瓶FALCON 中国（353014）Penicillin/streptomycin solution（KGY002）0.25% Tripsin-EDTA（BK-E3076）PBS（BK330-2）胎牛血清GIBCO 美国（10270-106）1640 培养基Hyclone 美国（SH3080901）Annexin V-FITC/PI 凋亡试剂盒 二、实验仪器表 2.2.1 主要
技术资料
